Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Immunotherapy Keeps Impressing in Advanced NSCLC, With Improvements on the Horizon

February 22nd 2021

Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice.

Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Rapid Readouts: Patient-Reported Outcomes from ADAURA

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Dr. Shu on the MOA of Amivantamab in EGFR Exon 20 Insertion–Mutated NSCLC

February 19th 2021

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.

Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer

February 18th 2021

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

Cemiplimab Significantly Improves Survival in Advanced NSCLC With PD-L1 of at Least 50%

February 18th 2021

February 18, 2021 - Single-agent cemiplimab has been found to result in a significant improvement in overall survival and progression-free survival versus chemotherapy in patients with advanced non–small cell lung cancer who had a PD-L1 expression of at least 50%.

Bad Company: Concurrent Mutations Define Unique Subsets of NSCLC

February 18th 2021

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

Dr. Liu on the Rationale for Examining Afatinib in NSCLC Harboring NRG1 Fusions

February 17th 2021

Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.

FDA Grants Priority Review to Sotorasib for KRAS G12C–Mutated Advanced or Metastatic NSCLC

February 17th 2021

February 16, 2021 - The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy

Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome

February 16th 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

Lurbinectedin/Irinotecan Shows Impressive Antitumor Activity in Relapsed SCLC

February 15th 2021

February 15, 2021 - The combination of lurbinectedin and irinotecan following relapse on frontline treatment was found to induce promising antitumor activity in patients with small cell lung cancer.

Recognizing the Value of Radiation Therapy in Lung Cancer

February 14th 2021

Randy Stevens, MD, discusses the growing role for radiation in lung cancer, delivery techniques, and adverse effect management strategies.

Dr. Weiss on the FDA Approval of Trilaciclib in Small Cell Lung Cancer

February 12th 2021

Jared Weiss, MD, discusses the FDA approval of trilaciclib in small cell lung cancer.

FDA Approves Trilaciclib to Reduce Chemo-Induced Bone Marrow Suppression in ES-SCLC

February 12th 2021

February 12, 2021 - The FDA has approved trilaciclib to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

February 10th 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities

February 10th 2021

Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 10th 2021

Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.

Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer

February 8th 2021

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

February 8th 2021

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.